GlassScriptPhysician profile
Christina Lam
NPI 1700171436
$24,421.28
in general payments reported to CMS, 2019-2025
33 companies · $5,754 in 2025
The $5,754 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,035 · 2022: $5,035 · 2023: $4,341 · 2024: $3,257 · 2025: $5,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,914.66 |
| Education | $436.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,938.43 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $2,644.87 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,991.72 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,935.19 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,912.71 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,681.14 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $1,664.45 | 2021-2022 | |
| Abbvie INC. | $1,455.72 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,217.71 | 2021-2025 | Fanapt, Hetlioz |
| Indivior INC. | $957.13 | 2022-2025 | Perseris, Sublocade |
| Lundbeck LLC | $947.23 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $648.20 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $590.92 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $585.60 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $398.21 | 2022-2025 | Auvelity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $380.25 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $345.49 | 2021-2023 | Jornay Pm |
| Corium, LLC | $335.85 | 2022-2024 | Azstarys, Azstarys |
| Collegium Pharmaceutical, INC. | $139.96 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $105.20 | 2021-2024 | Aplenzin |
| Tms Neurohealth Centers INC. | $98.30 | 2025 | Tms Neurohealth Centers INC. |
| Idorsia Pharmaceuticals US INC | $90.77 | 2023-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $72.20 | 2021-2022 | |
| Almatica Pharma LLC | $65.61 | 2022 | |
| Noven Therapeutics, LLC | $39.92 | 2021 | |
| Pfizer INC. | $38.27 | 2023 | |
| Lilly USA, LLC | $25.78 | 2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $25.40 | 2022 | |
| Biogen, INC. | $23.34 | 2025 | Zurzuvae |
| Biohaven Pharmaceuticals, INC. | $19.31 | 2021 | |
| Noven Pharmaceuticals, INC. | $17.89 | 2021 | |
| Adlon Therapeutics L.P. | $14.33 | 2021 | |
| Neos Therapeutics, LP | $14.18 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.